Docetaxel extravasation results in significantly delayed and relapsed skin injury: A case report
- Authors:
- Pei-Hung Chang
- Mei-Ti Wang
- Yi-Hua Chen
- Yu-Ying Chen
- Cheng-Hsu Wang
View Affiliations
Affiliations: Division of Hemato-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, Keelung 20445, Taiwan, R.O.C., Department of Pharmacy, Chang Gung Memorial Hospital, Keelung 20445, Taiwan, R.O.C.
- Published online on: February 27, 2014 https://doi.org/10.3892/ol.2014.1921
-
Pages:
1497-1498
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
Chemotherapeutic agents can result in extravasation, which is considered to be a serious complication. The increasing number of exposures to different cytotoxic agents experienced by each patient may enhance the prevalence of this complication. Docetaxel is widely used in the treatment of numerous solid tumors. Thus, the current report presents the case of a breast cancer patient who developed a significantly delayed skin reaction one day after docetaxel extravasation, a rare skin manifestation, and relapsed one week subsequently. This unusual clinical presentation is an indicator that practitioners are required to carefully monitor the patient for further cutaneous reactions in the weeks following extravasation to observe any additional adverse reactions.
View References
|
1
|
Bronner AK and Hood AF: Cutaneous
complications of chemotherapeutic agents. J Am Acad Dermatol.
9:645–663. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Albanell J and Baselga J: Systemic therapy
emergencies. Semin Oncol. 27:347–361. 2000.
|
|
3
|
Raley J, Geisler JP, Buekers TE and
Sorosky JI: Docetaxel extravasation causing significant delayed
tissue injury. Gynecol Oncol. 78:259–260. 2000. View Article : Google Scholar
|
|
4
|
Ener RA, Meglathery SB and Styler M:
Extravasation of systemic hemato-oncological therapies. Ann Oncol.
15:858–862. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ho CH, Yang CH and Chu CY: Vesicant-type
reaction due to docetaxel extravasation. Acta Derm Venereol.
83:467–468. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Susser WS, Whitaker-Worth DL and
Grant-Kels JM: Mucocutaneous reactions to chemotherapy. J Am Acad
Dermatol. 40:367–398. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Uña E, Cuadrillero F and López-Lara F:
Drug extravasation: a dreaded complication. BMJ Case Rep.
2009:bcr09.2008.0887. 2009.PubMed/NCBI
|
|
8
|
Ascherman JA, Knowles SL and Attkiss K:
Docetaxel (taxotere) extravasation: a report of five cases with
treatment recommendations. Ann Plast Surg. 45:438–441. 2000.
View Article : Google Scholar
|
